CONTEXT: Although GH promotes growth and protein anabolism, which are ATP-dependent processes, the GH effect on mitochondrial regulation remains to be determined. OBJECTIVE: Our objective was to determine the acute effect of GH on mitochondrial oxidative capacity in skeletal muscle of healthy subjects. DESIGN AND SETTING: The study was a randomized crossover design at an academic medical center. PARTICIPANTS: Nine healthy men and women completed the study. INTERVENTION: GH (150 microg/h) or saline was infused for 14 h on separate days, and muscle biopsies were obtained. MAIN OUTCOME MEASURES: Outcome measures included mitochondrial function, gene expression, and protein metabolism. RESULTS: The 4-fold increase in plasma GH caused elevations in plasma IGF-I, insulin, glucose, and free fatty acids and a shift in fuel selection, with less carbohydrate (-69%) and leucine (-43%) oxidation and 29% more fat oxidation. Muscle mitochondrial ATP production rate and citrate synthase activity were increased 16-35% in response to GH. GH also resulted in higher abundance of muscle mRNAs encoding IGF-I, mitochondrial proteins from the nuclear (cytochrome c oxidase subunit 4) and mitochondrial (cytochrome c oxidase subunit 3) genomes, the nuclear-derived mitochondrial transcription factor A, and glucose transporter 4. Although GH increased whole-body protein synthesis (nonoxidative disposal of leucine), no effect on synthesis rate of muscle mitochondrial proteins was observed. CONCLUSIONS: These results demonstrate that acute GH action promotes an increase in mitochondrial oxidative capacity and abundance of several mitochondrial genes. These events may occur through direct or indirect effects of GH on intracellular signaling pathways but do not appear to involve a change in mitochondrial protein synthesis rate.
RCT Entities:
CONTEXT: Although GH promotes growth and protein anabolism, which are ATP-dependent processes, the GH effect on mitochondrial regulation remains to be determined. OBJECTIVE: Our objective was to determine the acute effect of GH on mitochondrial oxidative capacity in skeletal muscle of healthy subjects. DESIGN AND SETTING: The study was a randomized crossover design at an academic medical center. PARTICIPANTS: Nine healthy men and women completed the study. INTERVENTION: GH (150 microg/h) or saline was infused for 14 h on separate days, and muscle biopsies were obtained. MAIN OUTCOME MEASURES: Outcome measures included mitochondrial function, gene expression, and protein metabolism. RESULTS: The 4-fold increase in plasma GH caused elevations in plasma IGF-I, insulin, glucose, and free fatty acids and a shift in fuel selection, with less carbohydrate (-69%) and leucine (-43%) oxidation and 29% more fat oxidation. Muscle mitochondrial ATP production rate and citrate synthase activity were increased 16-35% in response to GH. GH also resulted in higher abundance of muscle mRNAs encoding IGF-I, mitochondrial proteins from the nuclear (cytochrome c oxidase subunit 4) and mitochondrial (cytochrome c oxidase subunit 3) genomes, the nuclear-derived mitochondrial transcription factor A, and glucose transporter 4. Although GH increased whole-body protein synthesis (nonoxidative disposal of leucine), no effect on synthesis rate of muscle mitochondrial proteins was observed. CONCLUSIONS: These results demonstrate that acute GH action promotes an increase in mitochondrial oxidative capacity and abundance of several mitochondrial genes. These events may occur through direct or indirect effects of GH on intracellular signaling pathways but do not appear to involve a change in mitochondrial protein synthesis rate.
Authors: Madelon M Buijs; Johannes A Romijn; Jacobus Burggraaf; Marieke L De Kam; Adam F Cohen; Marijke Frölich; Frans Stellaard; A Edo Meinders; Hanno Pijl Journal: J Clin Endocrinol Metab Date: 2002-12 Impact factor: 5.958
Authors: Jonas Nygren; Anders Thorell; Kerstin Brismar; Pia Essén; Jan Wernerman; Margaret A McNurlan; Peter J Garlick; Olle Ljungqvist Journal: Clin Sci (Lond) Date: 2002-04 Impact factor: 6.124
Authors: Kevin R Short; Maureen L Bigelow; Jane Kahl; Ravinder Singh; Jill Coenen-Schimke; Sreekumar Raghavakaimal; K Sreekumaran Nair Journal: Proc Natl Acad Sci U S A Date: 2005-03-30 Impact factor: 11.205
Authors: Niels Jessen; Christian B Djurhuus; Jens O L Jørgensen; Lasse S Jensen; Niels Møller; Sten Lund; Ole Schmitz Journal: Am J Physiol Endocrinol Metab Date: 2004-08-31 Impact factor: 4.310
Authors: Craig S Stump; Kevin R Short; Maureen L Bigelow; Jill M Schimke; K Sreekumaran Nair Journal: Proc Natl Acad Sci U S A Date: 2003-06-13 Impact factor: 11.205
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Shana E McCormack; Meaghan A McCarthy; Loredana Farilla; Mirko I Hrovat; David M Systrom; Steven K Grinspoon; Amy Fleischman Journal: J Clin Endocrinol Metab Date: 2011-08-10 Impact factor: 5.958
Authors: Paul Fellinger; Peter Wolf; Lorenz Pfleger; Patrik Krumpolec; Martin Krssak; Kristaps Klavins; Stefan Wolfsberger; Alexander Micko; Patricia Carey; Bettina Gürtl; Greisa Vila; Wolfgang Raber; Clemens Fürnsinn; Thomas Scherer; Siegfried Trattnig; Alexandra Kautzky-Willer; Michael Krebs; Yvonne Winhofer Journal: JCI Insight Date: 2020-03-12
Authors: Kurt A Mossberg; William J Durham; Dennis J Zgaljardic; Charles R Gilkison; Christopher P Danesi; Melinda Sheffield-Moore; Brent E Masel; Randall J Urban Journal: J Neurotrauma Date: 2016-10-13 Impact factor: 5.269
Authors: Rocco Barazzoni; Kevin R Short; Yan Asmann; Jill M Coenen-Schimke; Matthew M Robinson; K Sreekumaran Nair Journal: Am J Physiol Endocrinol Metab Date: 2012-09-11 Impact factor: 4.310